Organization · Venture Capital
Catalys Pacific
Catalys Pacific is a venture capital firm focused on early-stage life sciences investments, particularly in biotech companies. With a presence in Japan and the United States, it aims to create and develop innovative healthcare solutions.
Overview
What Catalys Pacific does
What Catalys Pacific is
Catalys Pacific is a venture capital firm focused on early-stage life sciences investments, particularly in biotech companies. With a presence in Japan and the United States, it aims to create and develop innovative healthcare solutions.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 30, 2026
Official channels
Find Catalys Pacific elsewhere
Open the official website or a supported primary organization account.
Capability profile
Catalys Pacific as a funder
Investment thesis
Catalys Pacific focuses on transpacific company creation in life sciences, leveraging local expertise and partnerships to advance biotech innovations across Japan and the U.S.
Focus narrative
Catalys Pacific invests in early-stage biotech companies, particularly within the healthcare sector. The organization aims to maximize therapeutic impact for patients while providing attractive returns for investors. Its approach includes forming new companies around promising drug candidates and supporting their development through clinical trials and commercialization.
Value beyond capital
Catalys Pacific adds value to its portfolio companies through hands-on support in clinical development, leveraging its extensive network of R&D experts and strategic partners in the pharmaceutical and healthcare sectors. The firm focuses on creating bespoke biotech companies that can navigate the complexities of cross-border asset development.
Focus and fit
- Stages
- Seed · Series A · Growth Equity
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Aculys Pharma, HilleVax, and Phathom Pharmaceuticals
Portfolio context
Notable projects include: Mineralys: A targeted approach for the control of hypertension. Renalys: Focused on novel therapies for Asian patients with renal disease. Pathalys: Aimed at providing new solutions for patients with chronic kidney disease. Crystalys Therapeutics: A clinical-stage gout company with a $205M Series A financing. Aculys Pharma: A neurology-focused company that has been acquired.
Common questions
What to know about Catalys Pacific
Upseed classifies Catalys Pacific under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.